Enanta Pharmaceuticals is using our robust chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and liver diseases. With R&D efforts focused on respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV), Enanta continues to grow as we progress our pipeline.
We are seeking a highly motivated Scientist with a strong foundation in animal and/or biomedical sciences, including toxicology, pathology and physiology with proficient knowledge of developmental and reproductive biology, to join our Toxicology team. The successful candidate will assess preclinical safety of experimental compounds and will support drug development programs – from lead identification through clinical trial support – in a collaborative team environment, playing a pivotal role at all levels of preclinical development.
Oversee preclinical toxicology studies at external contract research organizations (CRO), including:
Facilitate study initiation by executing appropriate processes for contract implementation, test article procurement, protocol development, and timeline commitments.
Monitor studies for appropriate conduct, accuracy and timely completion; audit raw data for accuracy; and review draft reports for completion.
Anticipate study problems and opportunities and raise issues with suggested resolutions to supervisor.
Ensure appropriate project management and oversight with multiple CROs.
Evaluate individual and programmatic study data (anatomic pathology, clinical pathology, in-life parameters, etc.) as to the potential toxicity of experimental compounds in different animal species and prepare verbal and written summaries for internal discussions.
Work with the Toxicology team to develop optimal strategies to address specific safety issues and partner with project teams to select and advance Development compounds.
Serve as a key resource, providing scientific knowledge and expertise to cross-functional project teams.
Contribute to various regulatory documents and ensure regulatory compliance.
Build strong collaborative relationships with research and development teams to meet project, departmental, and company goals.
Education, prior work experience, and specialized skills and knowledge:
PhD in Toxicology, Pathology, or related health science field; Board Certification in Toxicology (ABT) strongly preferred, or
DVM/PhD or DVM
Solid foundation in animal and/or biomedical sciences, including toxicology, pathology, and physiology with proficient knowledge of developmental and reproductive biology
Excellent written and oral communication skills
Strong commitment to quality and accountability
Strong organizational and project management skills
Effective problem-solving skills and judgement
Able to work in a strong collaborative environment
In vivo study director experience preferred
Technical writing proficiency preferred
Direct experience with Good Laboratory Practices (CFR 21 Part 58) preferred
Collaboration & Teamwork: Advanced competence in collaboration & teamwork, communications influence, strategic agility, planning & organizing, driving results, and problem solving.
Productivity/Organizing/Planning: Meets deadlines, demonstrates effective use of time, and handles multiple assignments simultaneously.
Communication/Presentation Skills: Excellent ability to convey both written and verbal information effectively and efficiently and present information to all levels of audiences.
Willingness to Acknowledge Areas for Growth: Understands need for growth and is receptive to constructive feedback.
Leadership: Strong ability to establish and communicate clear visioning that team members willingly follow; provide information, knowledge and methods to realize that vision; coordinate and balance conflicting internal and external interests; ability to influence decision-making in a diplomatic manner. Able to navigate team smoothly through difficult situations.
Strategic Thinking: Capable of thinking conceptually, imaginatively, systematically, and opportunistically to achieve company goals.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.